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A B S T R A C T   
Background: Insight into patient characteristics that predict response to treatment for major depressive disorder 
(MDD) may help to personalize treatment and improve outcomes. One mechanism that has been linked to the 
success of treatment for MDD is brain-derived neurotropic factor (BDNF). BDNF is implicated in learning and 
memory and may play a role in the effects of psychotherapy that involves changing cognitions and behaviors. In 
addition, only in individuals with low BDNF, low working memory capacity has been associated with increased 
symptoms of depression. However, the role of BDNF and working memory capacity in psychotherapy outcome is 
unclear. The aim of this study was to investigate the role of BDNF and its interaction with working memory 
capacity in psychotherapy outcomes for MDD. 
Method: Adult patients with MDD were randomized to weekly or twice weekly sessions of cognitive behavioral 
therapy or interpersonal psychotherapy. BDNF Val66Met polymorphism (rs6265) (n = 138) was defined and 
serum BDNF was quantified before (n = 138) and after psychotherapy (n = 82). 
Results: Baseline serum BDNF and the Val66Met polymorphism were not associated with outcome and associa-
tions did not differ between treatment conditions. Working memory capacity significantly moderated the relation 
between baseline serum BDNF and outcome: high serum BDNF at baseline was related to less depressive 
symptoms following psychotherapy in the presence of high working memory capacity, but not low working 
memory capacity. 
Discussion: These findings, if replicated, might indicate that while BDNF may not be related to psychotherapy 
outcomes in general, they may play a role in the presence of specific learning processes such as working memory 
capacity.   
1. Introduction 
Depression is the leading cause of disability worldwide (World 
Health Organization, 2017) and although several equally effective 
treatments are available (Barth et al., 2013; Cuijpers et al., 2013), 
response rates need to be improved (Cuijpers et al., 2014; Dobson et al., 
2008). Depression can be treated with pharmacological treatment, 
psychotherapy or the combination of both (National Institute for Health 
and Care Excellence, 2018), but not each treatment might be the best fit 
for every patient. Insight into individual patient characteristics that 
predict response to treatment is therefore very important to personalize 
and optimize treatment effectiveness (Cohen and DeRubeis, 2018; 
Simon and Perlis, 2010). 
One factor that has been related to the success of treatment for 
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depression is brain-derived neurotrophic factor (BDNF) (Aldoghachi 
et al., 2019; Brunoni et al., 2008; Kishi et al., 2018; Molendijk et al., 
2011; Notaras et al., 2015; Polyakova et al., 2015; Sen et al., 2008). 
BDNF is a neurotrophin that plays a beneficial role in neurogenesis and 
is highly expressed the hippocampus (Balaratnasingam and Janca, 
2012), an area that is important for learning and memory (Burgess et al., 
2002) and in the regulation of stress (Dranovsky and Hen, 2006). 
Because the aim of psychotherapy is to change depressogenic cognitions 
and behavior with techniques that may require memory and learning 
(Bruijniks et al., 2019; Harvey et al., 2014; Lane et al., 2015), it is 
possible that high levels of BDNF could be a stimulator in providing a 
change in cognitions and behaviors that have been related to successful 
outcome (Adler et al., 2015; Kanter et al., 2010; Schmidt et al., 2019). 
BDNF seems therefore an interesting candidate predictor for psycho-
therapy outcome in depression. 
Some studies already investigated the relation of blood BDNF and 
genetic or epigenetic changes in BDNF and the effect of psychological 
treatments. For example, BDNF levels in serum measured before treat-
ment was lower in patients with poor response compared to patients 
with good response to 10 weekly sessions of group cognitive behavioral 
therapy (CBT) for panic disorder (Kobayashi et al., 2005). In addition, 
patients that carried Met-alleles on the Val66Met polymorphism, a ge-
netic variant of BDNF in which the Met-alleles are associated with less 
release of BDNF, showed lower response to 20 weekly sessions of CBT for 
obsessive compulsive disorder (OCD) compared to patients without 
Met-alleles (Fullana et al., 2012). One study into an intensive 4-week 
course of dialectal behavior therapy for patients with borderline per-
sonality disorders showed that those who responded to treatment 
showed a decrease in methylation of the BDNF gene over time (i.e., note 
that low methylation has been related to increased levels of BDNF; 
Perroud et al., 2013). In depression, a genetic variant of the BDNF 
(rs11030101) showed a preventive effect on deterioration in patients 
that did not receive treatment (Bakker et al., 2014). However, not all 
studies reported significant associations between serum BDNF and 
treatment outcomes. da Silva et al. (2018) showed that serum levels of 
BDNF measured in blood did not change after 16 weekly sessions of CBT 
for depression, while in another study BDNF measured in plasma did not 
predict response to 12 to 16 sessions of twice weekly IPT for depression 
(Koch et al., 2009). Also, the Val66Met polymorphism was not related to 
response in CBT for anxiety disorders (Santacana et al., 2016) or in a 
genome-wide meta-analysis of psychological treatment outcome for 
depression or anxiety (Rayner et al., 2019). 
Several factors may explain these inconsistent findings. First, many 
studies have only small sample sizes (n < 100). The power to find effects 
in small sample sizes is limited and can easily lead to null findings as 
sample sizes become smaller (Brookes et al., 2004). Second, studies are 
heterogeneous due to differences in populations or treatments. Third, 
the effect of BDNF might be moderated by individual characteristics. For 
example, the effect of the Val66Met polymorphism on remission of 
depression was seen in an Asian but not Caucasian population (Zou 
et al., 2010). One psychological construct that might moderate the role 
of BDNF in psychotherapy outcomes is working memory capacity. Like 
BDNF, working memory capacity has shown to be lower in patients with 
MDD (Beevers, 2005; Snyder, 2013) and both have been related to early 
life stress (Goodman et al., 2019; Zhao et al., 2017). Multiple studies 
have supported the genetic and epigenetic link between BDNF and 
working memory capacity (Brooks et al., 2014; Chen et al., 2016; 
Wagner et al., 2018), memory performance (Azeredo et al., 2017) or 
attention (Mikoteit et al., 2015). In the study of Chen et al. (2016), the 
relation between BDNF and working memory interacted with another 
gene that has repeatedly been linked to working memory: the 
Catechol-O-methyltransferase (COMT). Results showed that in in-
dividuals who were Val homozygote for BDNF, but not in BDNF 
Met-carriers, COMT Val homozygote was related to higher working 
memory capacity. 
Also, we have suggested that learning capacity (defined as the 
presence of neurobiological and cognitive processes related to learning, 
such as working memory capacity) may moderate the effects of CBT for 
depression (Bruijniks et al., 2019). One small study using a sample with 
subclinical symptoms of depression showed that in individuals with 
Met-alleles of the Val66Met polymorphism, but not in individuals 
without Met-alleles, low working memory capacity was associated with 
increased symptoms of depression over time (LeMoult et al., 2014). It 
was suggested that BDNF may increase or decrease depression through 
the way patients process new information (i.e., working memory ca-
pacity) (LeMoult et al., 2014). However, the study was underpowered 
and overall depression levels were low (LeMoult et al., 2014). Studies 
that investigate the direct link between BDNF, working memory and 
depressive outcome in a clinical sample that received psychotherapy are 
lacking. Investigating the hypothesis that the effect of BDNF is moder-
ated by working memory capacity in a larger and clinical sample might 
increase our insight into for whom and how BDNF mechanisms affect 
psychotherapy outcome for depression. 
Recently, we conducted a randomized trial that showed that twice 
weekly sessions of CBT and interpersonal psychotheray (IPT) led to more 
reduction in depression compared to weekly sessions (Bruijniks et al., 
2015, 2019). Using the data of this trial, the aim of the present study is 
twofold. Our first aim was to increase insight in whether BDNF plays a 
role in psychotherapy for depression. We did this by investigating 
change in serum BDNF from pre- to posttreatment and testing the effects 
of baseline serum BDNF and the Val66Met polymorphism as predictors 
of outcome. We hypothesized that serum BDNF would increase from pre- 
to posttreatment and that lower serum BDNF and Met-Alleles in the 
Val66Met polymorphism would predict worse outcome. In addition, 
because earlier we hypothesized that twice-weekly sessions lead to 
better outcomes compared to weekly sessions because a higher fre-
quency leads to better learning, reflected by a steeper increase in serum 
BDNF (Bruijniks et al., 2015), we exploratory tested whether the in-
crease in serum BDNF would be quicker and larger in the group that 
received twice weekly compared to weekly sessions of psychotherapy 
and whether the prediction of outcome with serum BDNF and 
Met-Alleles in the Val66Met polymorphism would differ between fre-
quency conditions. We conducted the same exploratory analyses for CBT 
versus IPT. Our second aim was to investigate if there would be a subset 
of patients showing a stronger relation between BDNF and depression. 
We expected that high levels of BDNF would lead to higher effects of 




The study was conducted in context of a large randomized trial that 
investigated the effects of session frequency and mechanisms of change 
in cognitive behavioral therapy and interpersonal psychotherapy for 
depression (Bruijniks et al., 2015). In this study, 200 patients were 
randomized to once versus twice weekly sessions of CBT and IPT over 
16–24 weeks up to a maximum of 20 sessions. Results showed that twice 
weekly sessions led to better depressive outcomes compared to weekly 
sessions (Bruijniks et al., 2020). Venipuncture was conducted before the 
start of treatment (T0, pretreatment) and 6 months (T1, posttreatment) 
after the start of treatment. Informed consent was signed before the start 
of the study. Participants were also allowed to participate in the study 
without participating in the venipuncture. Outcome measurements were 
completed at baseline, two weeks and monthly up to six months after 
start of treatment. For the present study, depression scores at baseline 
and six months after start of treatment and the baseline measurement of 
working memory capacity was used. Further details about the study 
protocol and study results can be found in Bruijniks et al. (2015) and 
Bruijniks et al. (2019). 
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2.2. Participants 
170 participants (85%) signed informed consent for venipuncture at 
the start of the study. Patients who provided consent for venipuncture 
did not differ in gender (t (198) = − 0.58, p = .55) or age (t (198) =
− 0.85, p = .39), but had significantly lower depression at baseline 
compared to patients who did not provide consent for venipuncture (no 
consent: M = 38.36 (SD = 9.69), consent: M = 34.05 (SD = 9.89), (t 
(198) = 2.20, p = .03). BDNF serum samples were available for 138 
participants at T0 and for 82 participants at T1. For 73 participants both 
T0 and T1 measurements were present. Patients who had BDNF rated on 
both time points did not differ in gender (t (146) = 0.79, p = .89), 
depression at baseline (t (146) = − 0.14, p = .88) or age (t (198) = − 1.75, 
p = .08) from those with BDNF measured at one time point only. The 
Val66Met polymorphism was present for 138 participants. Please also 
see the flow chart in Fig. 1 for an overview of exclusion reasons per 
measurement. 
2.3. Measurements 
2.3.1. Depression: Beck Depression Inventory II (BDI-II) 
Depression was measured by the Beck Depression Inventory. The 
BDI-II is a 21-item self-report instrument assessing depressive symptoms 
over the past two weeks. A score of 0–13 indicated minimal depression, 
14–19 mild depression, 20–28 moderate depression and 29–63 severe 
depression. Reliability and validity of the BDI-II has been supported 
(Beck et al., 1996; Beck et al., 1988; van der Does, 2002). 
2.3.2. Working memory: N-back task 
The n-back task has been regarded as a measure of working memory 
(WM) (Braver et al., 1997). During the n-back task participants were 
asked if a letter on the screen matched a letter previously (1-back, 2- 
back, 3-back) presented for 500 ms with an interval of 2000 ms. First, 
the participants were asked to run a test trial, where they got elaborate 
feedback about the incorrect responses (‘The previous letter was X, this 
indicated you had to press the button’). Second, the participants 
completed a 1-back trial (2 min) and a 2-back trial (two parts of 2.5 
Fig. 1. Flowchart. Note that for the Val66Met polymorphism originally data was missing for 36 patients, but that for four patients blood samples at T1 were available 
and were used to determine the Val66Met polymorphism. Also note that 73 patients had measurements of T0 and T1 BDNF serum levels and a total of 150 patients 
had a measurement on at least one of the measurements. 
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min). Only when the participants performed well on the 2-back (i.e. 2/3 
correct responses; a correct response means a correct press or a correct 
no-press), were they forwarded to the 3-back part of the task that also 
took 5 min (two parts of 2.5 min). The amount of n-backs (i.e. potential 
hits) in each condition was 33%. Feedback was given after a correct 
response (marked by a green V) or a miss (marked by a black X). WM 
load increased as the task progressed from 1-back to 3-back. The task 
took a maximum of 12.5 min and was completed at baseline. Accuracy of 
responses (total of correct hits (% correctly identified n-backs) and 
correct no hits (% correctly identified no presence of a n-back)) was 
measured and used as an outcome measure. Maximum score for each 
trial was 200, making the maximum score on all trials 1000 (results of 
the test trial were not included). Subsequently, the relative score was 
computed by individual score/1000 * 100. 
2.3.3. Blood sampling 
Blood samples (2 × 3 ml EDTA, 1 × serum tube) were collected at 
baseline and after six months by a research assistant at the patient’s 
home. After the venipuncture, serum samples were stored in the hospital 
nearby the mental health centre (i.e., VU Medical Centre for samples 
from GGZ inGeest, PsyQ Amsterdam and PsyQ Haarlem, Leids Univer-
sity Medical Centre for samples from PsyQ Leiden, Maastricht University 
Medical Centre for samples from Riagg Maastricht, Utrecht Medical 
Centre for samples from Altrecht, Radboud Medical Centre for samples 
from Pro Persona and GGZ Oss, Lab West (Medical Centre) for samples 
from PsyQ The Hague). Serum was centrifuged for 10 min on 1800 g at 
room temperature (20 ◦C), aliquoted into 0.5 ml samples and stored at - 
80 ◦C. The EDTA tubes from each research site were sent to VUmc where 
DNA was isolated using magnetic separation (PerkinElmer, U.S.A.) and 
stored at − 20 ◦C. 
2.3.4. Serum BDNF 
Prior to analysis, serum samples were thawed at room temperature, 
shortly vortexed and subsequently centrifuged at 10,000×g for 10 min. 
BDNF levels were measured using the commercially available and in 
house analytically validated BDNF Discovery Kit (Quanterix, USA) on 
board of the highly sensitive automated SIMOA HD-1 analyzer (Quan-
terix, USA). Samples were analyzed in duplicates, according to manu-
facturer’s instructions. Different time point per patients were analyzed 
within one plate. The mean coefficient of variation of the duplicate 
measurements was 2,8% (range 0–13%). 
2.3.5. Genotyping 
The 138 participants were genotyped with the Global Screening 
Array-24 v.1.0 (GSA) from Illumina (Human Genomics Facility, Erasmus 
MC, Rotterdam, the Netherlands). Quality control was performed with 
the RICOPILI pipeline developed by the Psychiatric Genomic Con-
sortium (Lam et al., 2019). For instance, duplicate samples, samples 
with sex mismatches, excess heterozygosity, and call rate were removed. 
Single genetic variants with a low (<0.98) call rate, minor allele fre-
quency (<0.01) and violated the Hardy-Weinberg equilibrium (p <
10− 6) were removed. The Val66Met polymorphism was not excluded in 
our sample after single variant QC thresholds were applied. Ancestry 
was determined based on principle component analysis. After quality 
control, missing data was imputed based on samples from the 1000 
Genomes Project (“International Genome Sample Resource (IGSR),” 
2019; The 1000 Genomes Project Consortium, 2012) as reference panel. 
The analyses of the Val66Met polymorphism (rs6265, position 
chr11:27658369) controlled for ethnic variety by excluding 
non-European participants (n = 32; U.S. National Library of Medicine, 
2019), leading to n = 106 patients for whom the Val66Met poly-
morphism was used in the analysis. 
2.4. Statistical analyses 
First, demographics and descriptives for each measurement were 
provided. Pearson correlations between baseline serum BDNF and pre- 
and posttreatment depression were calculated. Differences between re-
sponders and non-responders in serum BDNF and the presence of Met 
alleles in the Val66Met polymorphism were tested using an independent 
t-test and a chi-square test, respectively. Following cut-off scores for 
defining outcomes on the BDI-II in psychotherapy for depression (Riedel 
et al., 2010), response was defined as a drop of ≥47% points on the 
BDI-II from baseline to posttreatment. 
Second, we analyzed changes in serum BDNF and investigated 
baseline serum BDNF and the Val66Met polymorphism as a predictor of 
treatment outcome of MDD (BDI-II score at month 6). Change in serum 
BDNF during treatment was conducted with a repeated measure ANOVA 
with baseline BDI-II as a covariate. Exploratory analyses were conducted 
by adding frequency condition and treatment modality as a between 
factor in two separate analyses and investigating the interaction with 
change in BDNF. To investigate whether serum BDNF or the Val66Met 
polymorphism predicted outcome, multiple regression analyses were 
conducted with the BDI-II score at posttreatment as dependent variable, 
and serum BDNF at baseline or the Val66Met polymorphism (0 = Val/ 
Val, 1 = Val/Met, 2 = Met/Met) as the independent variable. Because 
previous studies indicated that gender, age, use of antidepressants, 
season of sampling, time of withdrawal, haven eaten prior to blood 
withdrawal (fasting status), and storage duration of the samples may 
have an influence on serum BDNF (Bus et al., 2011; Molendijk et al., 
2012; Ozan et al., 2010), we tested these variables as potential con-
founders by adding them separately into the regression model with 
baseline serum BDNF as independent variable (note that dichotomous 
variables were coded as follows: season of sampling: 0 = Octo-
ber–March, 1 = April–September; gender, 1 = male, 2 = female; use of 
antidepressants, 0 = no, 1 = yes, fasting status (on the day of veni-
puncture), 0 = no 1 = yes). Covariates were retained in the model if 
addition of the covariate changed the beta of the independent variable 
with >10%. All regression models included the BDI-II score at baseline 
and frequency condition as a predictor to control for initial depression 
severity and the effect of treatment. 
To investigate whether the prediction of serum BDNF or the Val66-
Met polymorphism on outcome was different between session frequency 
conditions, interactions (session frequency* serum BDNF and session 
frequency* Val66Met polymorphism; i.e., session frequency was already 
included as a main effect in each model to control for the effects of 
treatment) were added to the regression models for serum BDNF and 
Val66Met polymorphism, respectively. For testing the role of treatment 
modality, treatment modality (main effect) and interactions (treatment 
modality* serum BDNF and treatment modality * Val66Met poly-
morphism) were added to the final regression models for serum BDNF 
and Val66Met polymorphism, respectively. 
Third, moderation by working memory was investigated by adding 
an interaction between serum BDNF or the Val66Met polymorphism and 
working memory into the regression models (i.e., the models without 
the interactions). Effects were tested at p < .05. 
2.5. Ethics statement 
The authors assert that all procedures contributing to this work 
comply with the ethical standards of the relevant national and institu-
tional committees on human experimentation and with the Helsinki 
Declaration of 1975, as revised in 2008. All procedures involving human 
patients were approved by the Medical Ethical Committee of VU Medical 
Centre Amsterdam (registration number 2014.337). 
3. Results 
Of all participants for whom serum BDNF or the Val66Met poly-
morphism was analyzed (n = 150), 61.3% was female and the mean age 
at baseline was 38.82 (SD = 12.61). 26.4% of the participants used 
antidepressants. The sample was severely depressed on average 
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(baseline BDI-II: 33.88 (SD = 10). The extraction of the genotype of SNP 
rs6265 resulted in 73 individuals with Val/Val, 30 with Val/Met and 3 
with Met/Met genotypes (minor allele frequency: 0.17). Patients with 
different genotypes did not differ in age (F (2,103) = 0.53, p = .58) or 
gender (χ = 4.60, p = .10). Serum BDNF was 23.12 (SD = 7.2) and 
23.26 (SD = 6.72) in the participants for whom serum BDNF was 
measured both at baseline and posttreatment. General descriptives of 
participants included in one of the analyses can be found in Table 1. 
Demographics and observed means (SD) on all outcome measures at 
each time point for each sample and condition are given in data sup-
plement 1. As shown in Table 2, serum BDNF at baseline correlated 
highly (r = 0.61) with serum BDNF posttreatment, but not with BDI-II 
scores at baseline or posttreatment. 
3.1. Change of serum BDNF during psychotherapy for depression 
Serum BDNF did not change over time, F (1,71) = 0.03, p = .86. 
Change over time did not interact with baseline BDI-II scores, F (1,71) =
0.01, p = .90. Changes were not different between session frequency 
conditions, F (1,71) = 2.32, p = .13, or between treatment modalities, F 
(1,71) = 0, p = .99. 
3.2. Baseline serum BDNF and the Val66Met polymorphism as predictors 
of psychotherapy outcome 
After controlling for relevant confounders, higher levels of serum 
BDNF at baseline were not significantly related to lower levels of 
depression at month 6, t (7, 90) = -1.58, p = .11. The Val66Met poly-
morphism was not significantly related to lower levels of depression at 
month 6, t (3, 79) = − 2.07, p = .42. There were no significant in-
teractions between treatment condition (session frequency or treatment 
modality) and serum BDNF at baseline or the Val66Met polymorphism 
on outcome. The final regression models (without interactions) can be 
found in Table 3. Differences in serum BDNF and the presence of Met- 
alleles between responders and non-responders in are shown in 
Table 4. With mean baseline BDNF levels of 24.70 ng/ml in responders 
and 22.41 ng/ml in non-responders, these two groups did not differ 
significantly from each other (p = .07). Groups did also not differ on 
posttreatment serum BDNF (p = .87) or the presence of the Met-allele (p 
= .85). 
3.3. Working memory capacity as a moderator of the effect of serum 
BDNF or the Val66Met polymorphism on depressive outcome 
Working memory capacity (WMC) significantly moderated the effect 
of baseline serum BDNF on the BDI-II score at month 6, t (9, 65) =
− 2.15, p = .03 (see Table 5). WMC did not significantly moderate the 
effect of the Val66Met polymorphism on BDI-II at month 6, t (5, 57) =
− 0.74, p = .46. To illustrate the direction of the effect of working 
memory on the relation between baseline serum BDNF and depressive 
outcome, patients were assigned to a low WMC group when scoring 
below the mean and a high WMC group when scoring above the mean 
(WMC mean in the baseline serum BDNF group = 64.83, SD = 19.20, n 
= 96). As is shown in Fig. 2, high serum BDNF at baseline is related to 
lower BDI-II scores at month 6 in patients with high WMC (Pearson r =
− 0.35, p = .03, n = 40), but not in patients with low WMC (Pearson r =
.17, p = .31, n = 35). BDI-II scores at month 6 were lower for patients 
with a high WMC (M = 17.80, SD = 13.05, n = 40) compared to patients 
with a low WMC (M = 25.65, SD = 14.18, n = 35, t (73) = 2.49, p = .01), 
but did not differ between patients with high (>mean) serum BDNF 
levels at baseline (M = 20.70, SD = 15.38, n = 41) versus patients with 
low (<mean) serum BDNF levels at baseline (M = 21.16, SD = 12.24, n 
= 59, t (98) = 0.16, p = .86). 
Table 1 
General sample descriptives.  
Demographics  
Gender, n (%) female 92 (61.3) 
Age, M (SD) 38.82 (12.61) 
Educational level 
Low, n (%) 16 (10.7) 
Medium, n (%) 73 (48.7) 
High, n (%) 61 (40.7)  
Characteristics related to depression 
BDI-II baseline score 33.88 (10) 
BDI-II posttreatment 21.29 (14.71) 
Use of antidepressants, n (%) yes 39 (26.4)  
Potential moderators 
Working memory: n-back 64.55 (19.16)  
Table 2 
Correlations between different measures of BDNF and levels of depression.   
Serum BDNF – 
baseline (n) 
Serum BDNF - 








1    
Serum BDNF 
-month 6 (n) 
.61** (73) 1   
BDI-II baseline 
(n) 
.03 (138) .01 (82) 1  
BDI-II month 6 
(n) 
-.08 (103) -.04 (74) .44** (112) 1 
Note. BDI-II = Beck Depression Inventory-II; BDNF= Brain derived neurotrophic 
factor. ** = correlation is significant at p < .01. 
Table 3 
Predicting depressive outcome (BDI-II score at month 6) with serum BDNF at 
baseline (model 1) or the Val66Met polymorphism (model 2).   
B SE t p - value 95% CI 
Model 1: BDNF serum (n = 98) 
Intercept -6.61 8.26 -.80 .42 -23.03/9.80 
BDNF-serum baseline -.32 .20 -1.58 .11 -.73/.08 
BDI-II score baseline .52 .13 4.03 <.001 .26/.78 
Age .19 .10 1.82 .07 -.01/.40 
Female 5.88 2.73 2.15 .03 .45/11.32 
Use of antidepressants 6.37 2.85 2.24 .03 .72/12.04 
Fasting status .83 2.87 .29 .77 -4.87/6.53 
Frequency condition -2.56 2.55 -1 .31 -7.63/2.51  
Model 2: Val66Met polymorphism (n = 82) 
Intercept 4.82 5.21 .92 .36 -5.55/15.20 
Val66Met polymorphism -2.07 2.55 -.81 .42 -7.14/3.01 
BDI-II score baseline .55 .13 4.11 <.001 .28/.82 
Frequency condition -3.28 2.80 -1.17 .24 -8.85/2.29 
Note. Note that variables were coded as follows: Val66Met polymorphism = Val/ 
Val, 1 = Val/Met, 2 = Met/Met, gender, 1 = male, 2 = female; use of antide-
pressants, 0 = no, 1 = yes, fasting status, 0 = no (did eat), 1 = yes (did not eat), 
frequency condition, 0 = weekly, 1 = twice weekly. 
Table 4 
Differences between responders and non-responders in serum BDNF and the 
presence of Met-alleles.   








46 22.41 (6.45) 57 .07 




33 22.77 (6.88) 41 .87 
Presence of Met-allele, % 
yes 
29.7 11 34.7 16 .85 
Note. BDNF= Brain derived neurotrophic factor. 
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4. Discussion 
The present study investigated the role of brain-derived neurotrophic 
factor (BDNF) (serum levels and genetic polymorphism) in relation to 
change and outcome in cognitive behavioral therapy (CBT) and inter-
personal psychotherapy (IPT) for depression. Serum BDNF levels did not 
change during psychotherapy and changes did not significantly differ 
between session frequencies (once versus twice weekly) or treatment 
modalities (CBT versus IPT). Baseline serum BDNF and the Val66Met 
polymorphism were not significantly associated with outcomes after 6 
months and also this association did not differ between treatment con-
ditions. Working memory moderated the relation between baseline 
serum BDNF and outcome: higher baseline serum BDNF was related to 
lower posttreatment levels of depression, but only in the patients with 
high working memory. 
In line with the three other studies on the role of BDNF in psycho-
therapy for depression (Bakker et al., 2014; da Silva et al., 2018; Koch 
et al., 2009; Rayner et al., 2019), our findings suggested that BDNF 
levels on average do not play a role in the effects of psychotherapy for 
depression. Our findings contrast the other studies that found a relation 
between response to CBT and BDNF (Fullana et al., 2012; Kobayashi 
et al., 2005) in the treatment of anxiety disorders. It is possible that the 
role of BDNF differs between populations (i.e., depression versus 
anxiety), but also the limitations of a small sample size may explain this 
discrepancy. 
The finding that baseline serum BDNF levels were related to 
depressive outcome in the patients with high levels of working memory 
is in line with the findings of LeMoult (2014). That study particularly 
showed that in participants who were identified as Met-carriers, lower 
working memory capacity was associated with increased symptoms of 
depression over time. However, in the present study there was no rela-
tion between baseline serum BDNF and depressive outcome in patients 
with low working memory, but in the patients with high working 
memory. Differences between study populations may explain this 
discrepancy in findings. It is possible that although in individuals with 
subclinical depression (LeMoult et al., 2014), low BDNF and lower 
working memory capacity relates to an increase of depression over time, 
in a sample with severe levels of depression (our study) both high BDNF 
and working memory capacity are necessary in order to reduce 
depressive symptoms. Our results may suggest that there is a subgroup 
of depressive patients where learning processes such as working mem-
ory and BDNF levels are important in predicting treatment outcome, 
while for another subgroup they are not. Also, as moderators can help to 
identify mechanisms of change (Kazdin, 2007), our findings may point 
to different pathways of change for these different subgroups of patients. 
What are the potentially different pathways of change these sub-
groups might follow? One suggestion is that patients with higher 
learning processes at baseline may be better able to improve through the 
more cognitive part of CBT, cognitive change (Lorenzo-Luaces et al., 
2015), while those patients with lower learning processes may benefit 
from more direct CBT techniques, such as behavioral activation 
(Dimidjian et al., 2011). However, future research is necessary to find 
out whether patients with different learning processes at baseline, both 
measured at a biological and cognitive level, may benefit from different 
pathways of change (Bruijniks et al., 2019). In addition, studies should 
investigate whether learning processes are equally important in 
different forms of psychotherapy: while CBT has a clear skill-based 
approach (Barber and DeRubeis, 2001; Strunk et al., 2007), it is less 
clear how learning processes may play a role in IPT. Last, as those in-
dividuals with more impairments in the learning processes also had 
slightly higher BDI-II scores posttreatment, targeting the impairments in 
the learning processes in these individuals might be an opportunity to 
improve psychotherapy outcome (for an example: see Harvey et al., 
2017). 
A strength of the present study was the relatively large sample size 
compared to earlier studies (da Silva et al., 2018; Kobayashi et al., 2005; 
Koch et al., 2009). In addition, because of the large variation in 
participating treatment centers and inclusion of many therapists with 
varying educational backgrounds, external validity is considered high 
(Bruijniks et al., 2020). A limitation of the present study was that the 
sample was severely depressed on average, making it difficult to 
generalize these results to patients with less severe levels of depression. 
Also, although the present sample size was relatively large compared to 
earlier trials that investigated the role of BDNF in psychotherapy, the 
sample size was still rather limited to identify moderators (Brookes 
et al., 2004). Thus, especially the interaction we found between working 
memory and serum BDNF demands replication. 
Future studies should target the heterogeneity of previous findings 
by finding out whether BDNF plays a (different) role in the treatment of 
different psychopathologies, and investigate the role of BDNF in relation 
to working memory on depressive outcome in samples with larger 
variation in levels of depression at baseline. Also, both biological and 
psychological measures of learning processes at baseline should be 
included in future psychotherapy trials. As earlier studies pointed to an 
interaction between BDNF and COMT on working memory performance 
in healthy populations, it would be interesting for future studies to see 
whether the COMT plays a similar role in an psychotherapeutic setting 
(Chen et al., 2016; Nagel et al., 2008). With more data available, indi-
vidual participant data meta analyses (Debray et al., 2015; Riley et al., 
Table 5 
Interaction between serum BDNF at baseline and working memory capacity (n =
75).   
B SE t p - 
value 
95% CI 
Intercept -30.75 20.74 -1.48 .14 -72.18/ 
10.68 
Serum BDNF baseline 1.23 .77 1.59 .11 -.31/2.78 
Working memory capacity 
(WMC) 
.41 .27 1.51 .13 -.13/.95 
Serum BDNF baseline * 
WMC 
-.02 .011 -2.15 .03 -.04/-.002 
BDI-II score baseline .48 .14 3.34 .001 .19/.77 
Age .15 .11 1.25 .21 -.08/.38 
Female 5.49 3.01 1.84 .07 -.56/11.55 
Use of antidepressants 2.74 3.13 .87 .38 -3.52/9.01 
Fasting status 3.08 3.34 .92 .36 -3.59/9.76 
Frequency condition .61 2.74 .22 .82 -4.86/6.09 
Note. WMC = working memory capacity; Note that variables were coded as 
follows: gender, 1 = male, 2 = female; use of antidepressants, 0 = no, 1 = yes, 
fasting status, 0 = no (did eat), 1 = yes (did not eat), frequency condition, 0 =
weekly, 1 = twice weekly. 
Fig. 2. Interaction between serum BDNF at baseline and working memory 
capacity on depression (BDI-II score) at month 6. Black line = high working 
memory capacity (score > 64.83), grey line = low working memory capacity 
(score < 64.83). 
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Data supplement 1 
Sample characteristics: analyzed participants with serum BDNF measurements both at baseline and posttreatment (n=73), participants with a serum BDNF mea-
surement at baseline (n=138) and participants with the Val66Met polymorphism (n=106).  
Baseline serum BDNF and month 6 Whole group (n = 73) CBT weekly (n = 15) CBT twice weekly (n = 20) IPT weekly (n = 19) IPT twice weekly (n = 19) 
Demographics 
Gender, n (%) female 45 (61.6) 9 (60) 13 (65) 11 (57.9) 12 (63.2) 
Age, M (SD) 40.63 (12.77) 38.93 (14.45) 41.70 (10.13) 40.21 (12.63) 41.26 (14.75) 
Educational level 
Low, n (%) 5 (6.8) 1 (6.7) 1 (5) 2 (10.5) 1 (5.3) 
Medium, n (%) 37 (50.7) 8 (53.3) 10 (50) 8 (42.1) 11 (57.9) 
High, n (%) 31 (42.5) 6 (40) 9 (45) 9 (47.4) 7 (36.8)  
Depression 
BDI-II baseline score, M (SD) 34.04 (10.34) 36.06 (6.01) 35.70 (10.10) 33.47 (12.29) 31.26 (11.21) 
BDI-II posttreatment, M (SD) 19.59 (14.25) 23.85 (16.90) 15.72 (11.04) 21.80 (15.32) 18.36 (13.94) 
Use of antidepressants, n (%) yes 20 (27.8) 4 (26.7) 2 (10.5) 6 (31.6) 8 (42.1)  
Serum BDNF (ng/ml) 
Serum BDNF baseline, M (SD) 23.12 (7.20) 21.49 (5.60) 23.14 (7.32) 22.54 (7.74) 24.95 (7.75) 
Serum BDNF month 6, M (SD) 23.26 (6.72) 23.50 (7.41) 21.87 (7.16) 23.28 (5.69) 24.50 (6.89)  
Baseline serum BDNF Whole group (n ¼ 138) CBT weekly (n ¼ 36) CBT twice weekly (n ¼ 35) IPT weekly (n ¼ 34) IPT twice weekly (n ¼ 33) 
Demographics 
Gender, n (%) female 86 (62.3) 23 (63.9) 23 (65.7) 20 (58.8) 20 (60.6) 
Age, M (SD) 39.16 (12.62) 37.61 (13.73) 42.08 (11.65) 37.76 (11.87) 39.21 (13.10) 
Educational level 
Low, n (%) 15 (10.9) 4 (11.1) 5 (14.3) 4 (11.8) 2 (6.1) 
Medium, n (%) 69 (50) 15 (41.7) 18 (51.4) 16 (47.1) 20 (60.6) 
High, n (%) 54 (39.1) 17 (47.2) 12 (34.3) 14 (41.2) 11 (33.3)  
Depression 
BDI-II baseline score 33.97 (10.12) 35.11 (8.67) 35.51 (9.34) 32.17 (10.36) 32.96 (12.02) 
BDI-II posttreatment 21.05 (14.77) 23.82 (15.57) 18.92 (13.03) 21.20 (13.56) 20.20 (16.49) 
Use of antidepressants, n (%) yes 37 (27.2) 8 (22.2) 7 (21.2) 9 (26.5) 13 (39.4)  
Serum BDNF (ng/ml) 
Serum BDNF baseline, M (SD) 23.05 (6.38) 21.52 (6.02) 23.19 (5.95) 22.95 (6.84) 24.68 (6.60)  
Potential moderators 
Working memory: n-back 64.83 (19.20) 65.38 (20.66) 63.59 (18.58) 65.06 (18.42) 65.15 (20.17)  
BDNF Val66Met polymorphism Whole group (n ¼ 106) CBT weekly (n ¼ 26) CBT twice weekly (n ¼ 26) IPT weekly (n ¼ 28) IPT twice weekly (n ¼ 26) 
Demographics 
Gender, n (%) female 63 (59.4) 16 (61.5) 17 (65.4) 15 (53.6) 15 (57.7) 
Age, M (SD) 39.22 (12.38) 35.80 (13.42) 41.53 (10.95) 38.35 (12.08) 41.26 (12.78) 
Educational level 
Low, n (%) 12 (11.3) 2 (7.7) 4 (15.4) 3 (10.7) 3 (11.5) 
Medium, n (%) 49 (46.2) 10 (38.5) 11 (42.3) 16 (57.1) 12 (46.2) 
High, n (%) 45 (42.5) 14 (53.8) 11 (42.3) 9 (32.1) 11 (42.3)  
Depression 
BDI-II baseline score 33.67 (9.96) 35.57 (7.55) 36 (9.77) 32.64 (10.91) 30.57 (10.74) 
BDI-II posttreatment 20.87 (13.86) 22.70 (15.14) 18.23 (12.59) 22.63 (13.26) 20.26 (14.73) 
Use of antidepressants, n (%) yes 29 (27.6) 4 (15.4) 5 (20) 10 (35.7) 10 (38.5)  
Val66Met polymorphism 
Val-Val, n (%) yes 73 (68.9) 19 (73.1) 24 (92.3) 15 (53.6) 15 (57.7) 
Val-Met, n (%) yes 30 (28.3) 7 (26.9) 2 (7.7) 11 (39.3) 10 (38.5) 
Met-Met, n (%) yes 3 (2.8) 0 (0) 0 (0) 2 (7.1) 1 (3.8)  
Potential moderators 
Working memory: n-back 63.91 (18.53) 63.34 (19.67) 63.16 (18.67) 61.40 (17.22) 67.79 (19.45) 
Note. BDNF= Brain derived neurotrophic factor; BDI-II = Beck Depression Inventory-II. Note that there were missings at BDI-II scores posttreatment (serum BDNF 
baseline and month 6: 1 for CBT weekly 2 for CBT twice weekly 4 for IPT weekly; Serum BDNF baseline: 8 for CBT weekly, 9 for CBT twice weekly, 14 for IPT weekly, 4 
IPT for twice weekly; BDNF Val66Met polymorphism: 6 for CBT weekly, 5 for CBT twice weekly, 9 for IPT weekly, 3 IPT for twice weekly), use of antidepressants 
(Serum BDNF baseline and month 6: 1 for CBT twice weekly; Serum BDNF baseline: 2 for CBT twice weekly; BDNF Val66Met polymorphism: 1 for CBT twice weekly), 
working memory (Serum BDNF baseline: 11 for CBT weekly, 13 for CBT twice weekly, 9 for IPT weekly, 9 IPT for twice weekly; BDNF Val66Met polymorphism: 7 for 
CBT weekly, 8 for CBT twice weekly, 7 for IPT weekly, 7 IPT for twice weekly).  
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2010) might be an option to investigate moderators within a larger 
sample size. 
In conclusion, higher serum BDNF at baseline was related to lower 
posttreatment depression, but only in patients with high working 
memory. These findings, if replicated, might indicate that while BDNF 
may not be related to psychotherapy outcomes in general, they may play 
a role in the presence of specific learning processes such as working 
memory capacity. 
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